2
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Not yet recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Thoracic
1
Conditions
Breast Neoplasms
96
Rectal Neoplasms
45
Colorectal Neoplasms
45
Carcinoma, Non-Small-Cell Lung
31
Esophageal Neoplasms
28
Esophageal Squamous Cell Carcinoma
24
Stomach Neoplasms
22
Lung Neoplasms
20
Pancreatic Neoplasms
19
Squamous Cell Carcinoma of Head and Neck
18
Colonic Neoplasms
18
Sarcoma
16
Neoplasms
16
Adenocarcinoma Of Esophagus
15
Ovarian Neoplasms
14
Neoplasm Metastasis
14
Head and Neck Neoplasms
14
Carcinoma, Hepatocellular
14
Prostatic Neoplasms
13
Urinary Bladder Neoplasms
12
Uterine Cervical Neoplasms
10
Inflammatory Breast Neoplasms
9
Fallopian Tube Neoplasms
9
Osteosarcoma
8
Central Nervous System Neoplasms
8
Carcinoma, Intraductal, Noninfiltrating
8
Kidney Neoplasms
7
Carcinoma, Ovarian Epithelial
7
Recurrence
6
Multiple Myeloma
6
Interventions
Pemetrexed
14
Carboplatin
13
osimertinib
11
aflutinib
9
Drug Therapy
9
Gefitinib
8
Radiotherapy
6
Docetaxel
6
Cisplatin
6
pembrolizumab
5
anlotinib
5
Radiosurgery
5
Paclitaxel
5
icotinib
4
Vinorelbine
4
Gemcitabine
4
Erlotinib Hydrochloride
4
tislelizumab
3
camrelizumab
3
apatinib
3
HM781-36B
3
toripalimab
2
spartalizumab
2
rezivertinib
2
dacomitinib
2
Tyrosine Kinase Inhibitors
2
Thalidomide
2
Surgical Procedures, Operative
2
S 1 (combination)
2
Platinum
2
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
NSCLC
×
Neoadjuvant Therapy
×
Clear all
NCT07089199
2025-07-28
TitAN
Qilu Hospital of Shandong University
Phase 2
Not yet recruiting
34 enrolled